Institutional Repository of Vilnius University
(Epi)genomo tyrimai ir atsakas į KRAS izoformų raiškos nutildymą skirtingo piktybiškumo krūties vėžio ląstelių linijose /
Abstract
dc:descriptionBreast cancer is a heterogeneous disease whose progression and response to molecular interventions are determined by genetic and epigenomic changes. One of the key regulators of signaling pathways is the KRAS gene, which encodes a protein belonging to the small GTPase family. Although KRAS mutations are rarely detected in breast cancer, changes in its expression and epigenetic regulation may contribute to differences in the molecular properties of malignant cells. Since KRAS encodes two major isoforms KRAS-A and KRAS-B, their analysis may help better understand the role of KRAS in the response of breast cancer cells. This study evaluated epigenomic differences, KRAS isoform expression, and changes in selected response genes in the MCF-7 and MDA-MB-231 breast cancer cell lines. DNA methylation analysis was performed based on nanopore sequencing data, while the relative expression of the KRAS-A, KRAS-B, PRDX1, SOD1, and LOX genes was examined using the RT-PCR method. We also assessed how the expression of PRDX1, SOD1, and LOX changes following siRNA-mediated silencing of KRAS-A or both KRAS isoforms. The results showed that the MCF-7 and MDA-MB-231 cell lines differ in DNA methylation, KRAS isoform expression, and response to KRAS silencing. Hypermethylation was predominant in the more aggressive MDA-MB-231 line, and differences in KRAS gene methylation were more pronounced in the internal regions of the gene than in the promoter regions. KRAS-A expression was lower in MDA-MB-231 cells, and the most pronounced differences in relative expression of selected response genes were observed in the SOD1. Silencing of KRAS isoforms was more effective in MDA-MB-231 cells, but changes in the expression of PRDX1, SOD1, and LOX did not show a consistent, reproducible response in both cell lines. These results indicate that breast cancer cells of varying malignancy exhibit distinct epigenomic and transcriptional mechanisms that may influence the response to KRAS isoform silencing.
Degree
thesis:*- Grantor dc:publisher
- Institutional Repository of Vilnius University
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Ališauskaitė, Aiva,
Rights
dc:rights- Statement dc:rights
-
- info:eu-repo/semantics/openAccess
- Language dc:language
- lit
Identifiers
dc:identifier.*- Repository record dc:identifier
- https://repository.vu.lt/VU:ELABAETD308320536&prefLang=en_US